March 6, 2014 Mr. Nick Virca President and CEO, HedgePath Pharmaceuticals, Inc. nvirca@hedgepathpharma.com Dear Nick: Amendment No. 2 to Supply and License AgreementHedgePath Pharmaceuticals, Inc. • March 11th, 2014 • Services-commercial physical & biological research
We refer to the supply and license agreement dated, September 3, 2013, between Mayne Pharma International Pty Ltd and HedgePath Pharmaceuticals, Inc., as amended (Agreement). For due and valuable consideration, the receipt and sufficiency of which each party acknowledges, and in accordance with clause 26.8 of the Agreement, the parties agree to amend the Agreement, as set out below.
